Email
TextLatest News on Clinical Trials
Mount Sinai study reports asthma control in older patients and shows lower ED visits
Mount Sinai was part of the largest clinical trial for asthma self-management support in older patients, which resulted in improved control and quality of life, and fewer emergency department visits. Topic: Asthma affects 7 percent of Americans older than 65 and...
Detailed findings from CAROLINA® outcome trial support long-term cardiovascular safety profile of Tradjenta®
- CAROLINA® demonstrated no increased cardiovascular risk for Tradjenta® (linagliptin) versus glimepiride in the only active-comparator cardiovascular outcome trial for a dipeptidyl peptidase-4 (DPP-4) inhibitor - Adults with diabetes treated with Tradjenta...
Lannett Announces Initiation Of Human Clinical Trial Of Biosimilar Insulin Glargine Versus Us Lantus
Lannett Company, Inc. (NYSE: LCI) today announced the commencement of a human clinical trial of biosimilar insulin glargine, a product the company is co-developing with its strategic alliance partners within the HEC Group of companies (HEC). The trial, being...
BioXcel Therapeutics Completes Dosing Two Cohorts of Agitated Schizophrenia Patients with BXCL501 in a Phase 2 Efficacy Trial
Total of 96 agitated patients and healthy volunteers have received multiple doses of BXCL501, a proprietary sublingual thin film On track to announce top line results from Phase 2 efficacy trial in 3Q 2019 Planning to initiate first Phase 3 pivotal trial in 4Q 2019...
Goldfinch Bio Initiates Phase 1 Clinical Trial of GFB-887 for Kidney Disease
--First-in-Human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of GFB-887, a Targeted Podocyte-protective Therapeutic for the treatment of Focal Segmental Glomerulosclerosis, Treatment-resistant Minimal Change Disease and Diabetic Nephropathy--...
First patient dosed in the FRAMES phase 2 trial in Friedreich’s Ataxia
A double-blind, placebo-controlled trial aimed at assessing efficacy and safety of leriglitazone, up-regulated CNS disorders in Friedreich’s Ataxia patients Image Courtesy: Minoryx therapeutics Minoryx Therapeutics, a company specializing in the development of new...
CytoDyn and FDA Will Meet to Potentially Finalize Protocol for Pivotal Monotherapy Trial for Leronlimab
CytoDyn is also coordinating with an international public health agency to fully fund an HIV prevention study with leronlimab CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company”), a late stage biotechnology company developing leronlimab (PRO 140), a CCR5...
Homology Medicines Initiates Phase 1/2 Study for HMI-102 Gene Therapy Candidate for Adults with PKU and Expects Initial Clinical Results by Year End 2019
- Enrollment in the pheNIX Study Marks First Gene Therapy Clinical Trial for PKU - BEDFORD, Mass., June 10, 2019 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today that it has commenced enrollment of the Phase 1/2...
Two RISE Clinical Trials in Youth and Adults with Impaired Glucose Tolerance or Newly Diagnosed Type 2 Diabetes Reveal Surprising Differences in Beta-Cell (β-cell) Function During and After Treatment
RISE researchers present Adult Medication Study results at the ADA's Scientific Sessions and share the first direct comparison for youth and adult studies In a study measuring Beta-cell (β-cell) function in adults with impaired glucose tolerance (IGT) or newly...
Aerpio Initiates Phase 1b Clinical Trial of Topical Ocular Formulation of AKB-9778 for Primary Open Angle Glaucoma
Aerpio Pharmaceuticals, Inc. (Nasdaq: ARPO), a biopharmaceutical company focused on developing compounds that activate Tie2 to treat ocular diseases and diabetic complications, today announced dosing of the first subject in a Phase 1b trial of a topical ocular...
ProtoKinetix Achieves Primary Objective Safety at Midpoint of Clinical Trial
ProtoKinetix Incorporated (www.protokinetix.com) (the "Company" or "ProtoKinetix") (OTCQB:PKTX) today announced reaching the midpoint of a Phase-1 first-in-human clinical trial of AAGP® PKX-001 treated islet cells used in conjunction with the Edmonton Protocol for...
Sihuan’s Abstracts regarding Clinical Trial Progress of SGLT-2 Inhibitor Selected for Poster Presentation at the American Diabetes Association’s Scientific Sessions
Sihuan Pharmaceutical Holdings Group Ltd. (HKEx: 0460), the largest cardio-cerebral vascular drug manufacturer in China's prescription drug market, announced that three abstracts regarding the clinical trial of the Group's patented innovative drug Janagliflozin have...
Innovate Biopharmaceuticals Announces the Start of the First Phase 3 Clinical Trial in Celiac Disease
Launch of the first ever phase 3 trial in the history of celiac disease Innovate Biopharmaceuticals, Inc. (Nasdaq:INNT), a clinical stage biotechnology company focused on developing novel therapeutics for autoimmune and inflammatory diseases, announced the start of...
Zafgen Presented Full Results of Phase 2 Clinical Trial for ZGN-1061 at the American Diabetes Association’s 79th Scientific Sessions
Delivered comprehensive oral presentation on both cohorts of the clinical trial, including previously announced results for second cohort evaluating doses up to 1.8 mg Company also presented data demonstrating that treatment with ZGN-1061 improves measures of insulin...
Positive Feline Clinical Trial Outcome Motivates Sorrento Therapeutics to Accelerate Human IND Filing of Resiniferatoxin (RTX) for Prolonged Non-Opioid Control of Post-Amputation Neuropathic Pain
Sorrento Therapeutics, Inc. (NASDAQ: SRNE, "Sorrento"), announced that review of early results from an on-going “declawed cat pain trial” (run by its Ark Animal Health division) prompted management to assign a high priority to exploring the use of resiniferatoxin as a...
PharmaCyte Biotech CEO in Thailand to Oversee Production of Final Clinical Trial Material for IND Submission
PharmaCyte Biotech, Inc. (PMCB), a clinical stage biotechnology company focused on developing targeted cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today announced that its Chief Executive Officer,...
Eloxx Pharmaceuticals’ Phase 2 Study of ELX-02 in Cystinosis Receives Authorization of Clinical Trial Application (CTA) by Health Canada and Funding from Genome Quebec and Genome Canada
Dr. Paul Goodyer, a Professor of Pediatrics at McGill University and recognized leader in hereditary renal disease, will be the principal investigator in the Phase 2 clinical trial Genome Quebec and Genome Canada provides non-dilutive funding for the Phase 2 clinical...
Immunicom Announces First Patient Enrollment in Multi-Center, Triple-Negative Breast Cancer Clinical Trial
Immunicom, Inc., a medical technology company awarded FDA Breakthrough Device Designation for Immunopheresis™, its non-pharmaceutical solution for treating stage IV metastatic cancer, began treating its first of 170 triple-negative breast cancer (TNBC) patients...
vTv Therapeutics Announces Positive Topline Results from Part 1 of the Phase 2 Simplici-T1 Trial in Patients with Type 1 Diabetes
HIGH POINT, N.C.--(BUSINESS WIRE)--vTv Therapeutics Inc. (Nasdaq: VTVT) today announced positive results from the primary analysis of Part 1 of the Phase 2 Simplici-T1 trial assessing the liver-selective glucokinase activator TTP399 in adult patients with type 1...
INSIGHT: First Patient Dosed in the 4th arm called “INSIGHT-004”
Highlights First patient received first dose in INSIGHT-004, a phase I clinical trial Evaluates the combination of eftilagimod alpha with avelumab (BAVENCIO®) in different cancer indications Patient recruitment for the trial is ongoing in Germany, with first data...